key: cord-0282959-ht1gv5li
authors: Eyer, Ludek; Nougairède, Antoine; Uhlířová, Marie; Driouich, Jean-Sélim; Zouharová, Darina; Valdés, James J.; Haviernik, Jan; Gould, Ernest A.; De Clercq, Erik; de Lamballerie, Xavier; Ruzek, Daniel
title: An E460D substitution in the NS5 protein of tick-borne encephalitis virus confers resistance to the inhibitor Galidesivir (BCX4430) and also attenuates the virus for mice
date: 2019-02-28
journal: bioRxiv
DOI: 10.1101/563544
sha: 0ae0e227f20960cc18b33946a7c92969dfac79a2
doc_id: 282959
cord_uid: ht1gv5li

The adenosine analogue Galidesivir (BCX4430), a broad-spectrum RNA virus inhibitor, has entered a Phase 1 clinical safety and pharmacokinetics study in healthy subjects and is under clinical development for treatment of Ebola virus infection. Moreover, Galidesivir also inhibits the reproduction of tick-borne encephalitis virus (TBEV) and numerous other medically important flaviviruses. Until now, studies of this antiviral agent have not yielded resistant viruses. Here, we demonstrate that an E460D substitution, in the active site of TBEV RNA-dependent-RNA-polymerase (RdRp), confers resistance to Galidesivir in cell culture. Stochastic molecular simulations indicate that the steric freedom caused by the E460D substitution increases close electrostatic interactions between the inhibitor and the interrogation residue of the TBEV RdRp motif F, resulting in rejection of the analogue as an incorrect/modified nucleotide. Galidesivir-resistant TBEV exhibited no cross-resistance to structurally different antiviral nucleoside analogues, such as 7-deaza-2’-C-methyladenosine, 2’-C-methyladenosine and 4’-azido-aracytidine. Although, the E460D substitution led only to a subtle decrease in viral fitness in cell culture, Galidesivir-resistant TBEV was highly attenuated in vivo, with 100% survival rate and no clinical signs observed in infected mice. Our results contribute to understanding the molecular basis of Galidesivir antiviral activity, flavivirus resistance to nucleoside inhibitors and the potential contribution of viral RdRp to flavivirus neurovirulence. Importance Tick-borne encephalitis virus (TBEV) is a pathogen that causes severe human neuroinfections in large areas of Europe and Asia and for which there is currently no specific therapy. We have previously found that Galidesivir (BCX4430), a broad-spectrum RNA virus inhibitor, which is under clinical development for treatment of Ebola virus infection, has a strong antiviral effect against TBEV. For any antiviral drug, it is important to generate drug-resistant mutants to understand how the drug works. Here, we produced TBEV mutants resistant to Galidesivir and found that the resistance is caused by a single amino acid substitution in an active site of the viral RNA-dependent RNA polymerase, an enzyme which is crucial for replication of viral RNA genome. Although, this substitution led only to a subtle decrease in viral fitness in cell culture, Galidesivir-resistant TBEV was highly attenuated in a mouse model. Our results contribute to understanding the molecular basis of Galidesivir antiviral activity.

active site of the viral RNA-dependent RNA polymerase, an enzyme which is crucial for 50 replication of viral RNA genome. Although, this substitution led only to a subtle decrease in 51 viral fitness in cell culture, Galidesivir-resistant TBEV was highly attenuated in a mouse 52 model. Our results contribute to understanding the molecular basis of Galidesivir antiviral 53 activity. 54

Introduction on the host cells (Eyer et al., 2017a) . A Phase 1 clinical safety and pharmacokinetics study in 87 healthy subjects has been completed, and at present, Galidesivir is under clinical 88 development as an antiviral drug for treatment of Ebola virus infection (Taylor et al., 2016) . 89

The broad-spectrum antiviral activity makes this drug a promising candidate for 90 development of therapy not only for Ebola virus infection but also other important diseases 91 caused by various RNA viruses, including TBEV. 92

Although Galidesivir has been studied intensively and is known to inhibit a wide 93 range of RNA viruses, there are no published reports of resistance to this compound. frequency is estimated to be 10 −4 to 10 −6 errors per nucleotide (Lauring et al., 2013) . The 98 high mutation frequency and high replication rate of viral RNA copies enable the viruses 99 quickly to adapt to changes in the environment, including the introduction of antiviral drugs. 100

Identification of mutations conferring antiviral resistance provides information not only 101 7 fragments into permissive BHK-21 cells, the following recombinant TBEV strains were 151 successfully rescued: E460D-Rec (E460D substitution in the NS5 gene), Y453H-Rec (Y453H 152 substitution in the NS5 gene), and recombinant wild-type (no introduced mutations). The 153 presence of the E460D and Y453H substitutions in the viral genomes was confirmed by 154 whole-genome sequencing of all recombinant viruses. Despite repeated attempts, the 155 E460D/Y453H-Rec mutant (both mutations E460D and Y453H in the NS5 gene) was not 156 rescued from the transfected BHK-21 cell culture. E460D-Rec was found to be 7.9-fold less 157 sensitive to Galidesivir than engineered wild-type, showing an EC50 value of 6.32 ± 1.01 µM 158 (Table 2) . On the other hand, Y453H-Rec was highly sensitive to Galidesivir; the replication of 159 this mutant strain was completely inhibited at 12.5 µM, showing an EC50 value of 0.81 ± 0.01 160 µM (Table 2) . Thus, the results indicate, that the E460D (not Y453H) substitution is solely 161 responsible for the drug-resistant phenotype of TBEV ( Figure 2A ). 162

The E460D mutation has only a moderate effect on TBEV replication in cell culture 164

To characterize the phenotypic properties of the drug-resistant mutant in vitro, 165 growth kinetics ( Figure 2B ) and plaque morphology ( Figure 2C ) of the recombinant TBEV 166 mutant E460D-Rec were assayed in cultures of PS cells and compared with the wild-type 167 virus. The wild-type virus amplified in the absence of Galidesivir ( Figure 2B , red line), showed 168 a short lag-period within intervals 0 -12 hours p.i. Starting 24 hours p.i., the wild-type TBEV 169 exerted an exponential increase in virus infectivity reaching a peak titre of 3x10 6 PFU/mL 170 within 72 hours p.i. and gradually declining thereafter. In contrast, the presence of 171 Galidesivir (25 µM) completely inhibited replication of the wild type virus ( Figure 2B , violet 172 line). 173

In comparison with the wild-type virus, the E460D-Rec mutant cultured in the 174 absence of Galidesivir ( Figure 2B , blue line) showed a prolonged lag-period within intervals 0 175 -36 hours p.i. However, subsequently, the infectivity of the mutant virus increased 176 exponentially reaching a peak of 2.6x10 6 PFU/mL at 72 hours p.i. After that, the titre 177 gradually declined to 5.5x10 4 PFU/mL. The considerably longer lag-period of the E460D-Rec 178 mutant could be explained by a slightly decreased replication capacity (attenuation) of the 179 mutant, when amplified in PS cell culture. The decrease in replication capacity of E460D-Rec 180 was manifested particularly in the first few hours after cell culture infection and was no 181 longer detecable in the later stages of the infection.

The E460D-Rec mutant cultured in the prensence of Galidesivir (25 µM) ( Figure 2B , 183 green line) also exerted an extended lag-period within intervals 0 -36 hours p.i.; there was 184 even a moderate decrease in viral titers after 36 hours p.i. Starting 48 hours p.i., the mutant 185 showed an exponential infectivity and reached a peak titre of 3.9x10 5 PFU/mL at day 96 186 hours p.i. The results clearly indicate, that the resistance of TBEV to Galidesivir is only partial; 187 the growth of the mutant strain in the presence of Galidesivir was partially inhibited 188 compared to wild-type ( Figure 2B In general, mutant genotypes rapidly revert to the wild-type in the absence of the 227 selection agents. Indeed, after three passages in PS cells in the absence of Galidesivir a pool 228 comprising mutated and wild-type genotypes was detected. Moreover from passage 5 229 onwards, the wild-type genotype dominated in the infected PS cell culture ( Figure 1E ). 230

Interestingly, the codon GAT encoding an aspartic acid in the E460D mutant had changed to 231 the codon GAA in the revertant, not to GAG as seen in mock-selected wild-type virus; both 232 codons, GAA (in the revertant) and GAG (in the wild-type), are synonymous and encode a 233 glutamic acid residue ( Figure 1F ). In contrast, after 6 passages in the presence of Galidesivir, 234 at concentrations up to 25 µM, the E460D substitution was retained; even at low 235 concentrations of Galidesivir (6.25 µM) and did not result in reversion to the wild-type 236 genotype (data not shown). 237 238 Galidesivir migration towards the TBEV RdRp active site 239

The deduced position of Galidesivir bound within the TBEV RdRp active site is shown 240 in Figure 4A with its phosphate tail forming close contacts with the manganese cofactors. 241

The E460D (and Y453H) mutation is located at motif F of the flavivirus RdRp finger domain. 242

The flavivirus RdRp motif F is highly flexible and occludes the NTP-tunnel in the nucleotide 243 bound RdRp structure (Valdés et al., 2016) . Therefore, the apo-structure was used for 244 stochastic simulations to compare and contrast how Galidesivir approaches the TBEV active 245 site in the wild type and mutant RdRps. At the active site of the wild type TBEV RdRp, the 246 ribose of Galidesivir is at a 5.7 Å distance from amino acid (aa) position 460. The missing 247 carbon in Asp increases this distance (7 Å) compared to Glu. This increased distance, caused 248 by the mutation, results in more steric freedom for Galidesivir as it approaches the active 249 site ( Figure 4B,C) . 250

There is a ~6.7 Å distance cutoff by Galidesivir approaching the wild type TBEV RdRp 251 active site that is explored closer (<5 Å) in both mutant types ( Figure 4B ). The single RdRp 252 mutation, E460D, however, has lower enthalpic ligand binding values compared with the 253 double mutant, E460D/Y453H. These lower enthalpic values indicate a favorable ligand 254 binding and conformation. The distinct differences in Galidesivir exploration between the 255 wild type and mutant RdRps are shown by the average COM distance/enthalpy in Figure 4B , 256 specifically those by the single E460D mutation (wild type: 11.3 Å  4.6 Å/-179.9 kcal/mol  257 121.9 kcal/mol, E460D: 9.5 Å  4.9 Å/-257.3 kcal/mol  121.2 kcal/mol; E460D/Y453H: 10.6 Å 258 Data are expressed as means ± SD, and the significance of differences between 521 groups was evaluated using the Mann-Whitney U test or ANOVA. Survival rates were 522 analysed by log-rank Mantel-Cox test. All tests were performed using GraphPad Prism 5.04 523 (GraphPad Software, Inc., San Diego, CA, USA). P-values < 0.05 were considered to be 524 statistically significant. The reverse genetics method used in this study was based on the generation of infectious 707 Table 1 . Unmodified and mutated primers used to generate two overlapping amplicons of 720 fragment III (fragment IIIa and IIIb), i.e. to produce recombinant wild-type and mutated and cultivated at Galidesivir concentrations ranging from 0 to 50 µM for three days.

Tick-borne encephalitis

Escape of tick-borne flavivirus from 2' -C-methylated 568 nucleoside antivirals is mediated by a single conservative mutation in NS5 that has a 569 dramatic effect on viral fitness

Nucleoside analogs as a rich source of 572 antiviral agents active against arthropod-borne flaviviruses

Structure-activity relationships of nucleoside analogues 575 for inhibition of tick-borne encephalitis virus

Nucleoside Inhibitors of Tick-Borne Encephalitis Virus

Antiviral activity of the adenosine analogue BCX4430 against West Nile virus 580 and tick-borne flaviviruses

Effectively 596 Treats Yellow Fever in a Hamster Model

Efficacy of the broad-spectrum antiviral compound 599 BCX4430 against Zika virus in cell culture and in a mouse model

The Attenuation Phenotype of a

Porcine Reproductive and Respiratory Syndrome Virus Is 603 Maintained during Sequential Passages in Pigs.nJ Virol

Pig Kidney Epithelial (Ps) Cells -Perfect Tool for Study of Flavi-606 Viruses and Some Other Arboviruses

The role of mutational robustness in RNA virus evolution

doi: terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

Isolation of new strains of meningoencephalitis virus in 619 the Brno region druing the summer of 1953

Update on hepatitis C 621 virus resistance to direct-acting antiviral agents

Mutations in the NS2B and NS3 genes affect mouse neuroinvasiveness

Tick-borne encephalitis: Pathogenesis 628 and clinical implications

BCX4430-A broad-spectrum antiviral adenosine 631 nucleoside analog under development for the treatment of Ebola virus disease

Flaviviridae viruses use a common molecular 634 mechanism to escape nucleoside analogues

An all-atom, active site exploration of 637 antiviral drugs that target flaviviridae polymerases

Protection against filovirus diseases by a novel broad-639 spectrum nucleoside analogue BCX4430

resistance phenotype. (B) Growth kinetics of the E460D-Rec mutant and 670 wild-type TBEV in the presence (25 µM) or absence

D-E) The sensitivity/resistance profiles 674 of the E460D/Y453H, E460D-Rec, and Y453H-Rec to diverse nucleoside inhibitors 675 (concentrations of 25 µM (D) and 50 µM (E)) were evaluated in PS cells and compared with 676 the corresponding wild-type TBEV. The mean titers from two independent experiments

Phenotypic properties of the TBEV mutant resistant to Galidesivir in mice. The extent